查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933363

全球氨基糖苷類抗生素市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素及未來預測（2026-2034）

Aminoglycosides Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

氨基糖苷類抗生素市場成長驅動因子

預計2025年全球氨基糖苷類抗生素市場規模將達19.2億美元，2026年將達19.6億美元。預計2034年將成長至25.2億美元，預測期內複合年增長率（CAGR）為3.17%。北美地區憑藉其完善的醫療保健基礎設施、強大的購買力和許多大型企業的強大影響力，在2025年佔市場主導地位，市場佔有率達41.31%。氨基糖苷類抗生素是一類廣泛用於治療複雜性泌尿道感染（cUTI）、敗血症、醫院獲得性肺炎、囊性纖維化等呼吸系統疾病的殺菌性抗生素。 新黴素、妥布黴素、慶大霉素、阿米卡星、巴龍黴素和鏈黴素等藥物因其與β-內酰胺類抗生素對多重抗藥性細菌具有協同作用，尤其是在重症監護病房中，在臨床實踐中繼續發揮著重要作用。吸入製劑和半合成衍生物等技術進步提高了藥物傳遞效率和安全性。 Hikma Pharmaceuticals、輝瑞和Cipla等領導者憑藉豐富的產品組合和地理擴張，保持著市場主導地位。 市場動態 驅動因素：泌尿道感染（UTI）發生率的上升推動了氨基糖苷類藥物處方量的增加。導致這一增長的因素包括人口老化、糖尿病盛行率上升以及發展中地區醫院感染的流行。例如，2024年2月，印度藥品監管局（CDSCO）批准了西普拉公司（Cipla）的新型靜脈注射氨基糖苷類抗生素普拉佐米星（plazomicin），用於治療包括腎盂腎炎在內的複雜性泌尿道感染。

限制因素：抗菌藥物抗藥性（AMR）的出現威脅著市場成長。大腸桿菌、肺炎克雷伯菌和綠膿桿菌的抗藥性日益增強，使治療效果複雜化。 2023年7月，美國疾病管制與預防中心（CDC）報告稱，耐碳青黴烯類腸桿菌科細菌（CRE）和抗氨基糖苷類革蘭氏陰性菌的數量增加。同樣，歐洲疾病預防控制中心（ECDC）指出，在多個歐盟國家，肺炎克雷伯菌血流感染的抗藥性率超過25%。

機會：肽鏈氨基糖苷類藥物的開發可望用於對抗多重抗藥性病原體。 2025年8月發表於 "微生物學前沿" （Frontiers in Microbiology）的一項研究強調了肽新黴素複合物與多粘菌素B聯合用藥對多重抗藥性革蘭氏陰性菌的協同作用，表明其具有廣闊的應用前景。

挑戰：耳毒性和腎毒性仍然是主要問題。即使在治療劑量下，攜帶罕見粒線體突變的患者也容易出現不可逆的聽力喪失。 2021年1月，英國政府報告​​稱，氨基糖苷類藥物的治療窗較窄，凸顯了其在急診環境中的臨床挑戰，並限制了其廣泛應用。

市場趨勢

聯合療法的應用正日益普及。 氨基糖苷類藥物目前常被納入多重藥物合併療法，用於治療由鳥分枝桿菌複合群 (MAC) 引起的非結核分枝桿菌 (NTM) 肺病等疾病。這種方法可以提高療效，延緩抗藥性的產生，並延長現有抗生素的治療壽命。 2021 年 3 月，Insmed 公司在日本核准上市的 Arikace（阿米卡星脂質體吸入混懸液），這是一種用於治療非結核分枝桿菌 (NTM) 肺病的聯合療法。

市場區隔分析

依世代劃分：第三代氨基糖苷類藥物因其對多重抗藥性感染的有效性而佔主導地位。諸如四環藥業控股有限公司與上海盛亞醫藥股份有限公司於 2022 年 6 月達成的合作協議等戰略聯盟，為普拉唑米星等第三代藥物的研發提供了支持。

依適應症劃分：呼吸道感染佔比最大。這主要是由於呼吸道感染的高發生率和治療複雜性，尤其是在囊性纖維化患者。美國疾病管制與預防中心 (CDC) 在 2024 年 5 月報告稱，美國約有 35,000 人患有囊性纖維化，這推動了對氨基糖苷類藥物的需求。

依給藥途徑劃分：外用製劑因其局部療效、全身吸收少以及新產品不斷上市而佔主導地位。例如，Apili Therapeutics 於 2024 年 10 月開發了用於治療皮膚利甚曼病的外用巴龍黴素製劑 ATI-1801。

依分銷管道劃分：零售藥局因其便利性、病患信任度和不斷擴大的網路而處於領先地位。 2024年9月，Pharmaprix在魁北克省擴建了其護理診所，以改善氨基糖苷類藥物的可及性。

區域展望

北美：在策略合作、研發投資和強大的醫療保健體系的支持下，預計到2025年，市場規模將達到7.9億美元。

歐洲：在強大的醫療保健基礎設施和抗菌藥物管理計畫的支持下，預計到2025年，市場規模將達到4.9億美元，成長率為2.80%。

亞太地區：預計到2025年，市場規模將達到3.2億美元，這反映了抗生素可近性的擴大和傳染病患者病率的上升。

拉丁美洲、中東和非洲：受醫療保健支出成長的推動，預計拉丁美洲市場將成長2億美元，中東和非洲市場也將成長，但增幅較小，預計成長速度將較為溫和。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 各國及地區主要疾病概覽（2025 年）
  • 各國及地區監理現況（2025 年）
  • 主要公司產品線分析
  • 抗生素治療指引概覽
  • 世衛組織重點病原體抗生素抗藥性概覽
  • 主要產業趨勢：併購、業務合作等等。

第五章 全球氨基糖苷類抗生素市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依代劃分
    • 第一代
    • 第二代
    • 第三代
    • 其他
  • 市場分析、洞察與預測：依應用劃分
    • 泌尿道感染
    • 呼吸道感染
    • 皮膚感染
    • 眼部感染
    • 其他
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 腸外給藥
    • 外用
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美氨基糖苷類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲氨基糖苷類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區氨基糖苷類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲氨基糖苷類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

章節10：中東和非洲氨基糖苷類抗生素市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第 11 章 競爭分析

  • 全球市佔率分析（2025）
  • 公司簡介
  • Amneal Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals PLC
  • Insmed Incorporated
  • Pfizer Inc.
  • Cipla
  • Nordic Group B.V.
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
Product Code: FBI113880

Growth Factors of aminoglycosides Market

The global aminoglycosides market was valued at USD 1.92 billion in 2025 and is projected to reach USD 1.96 billion in 2026, eventually growing to USD 2.52 billion by 2034, reflecting a CAGR of 3.17% during the forecast period. North America dominated the market in 2025 with a 41.31% share, owing to robust healthcare infrastructure, high purchasing capacity, and a strong presence of key players. Aminoglycosides are a class of bactericidal antibiotics widely employed in treating complicated urinary tract infections (cUTIs), sepsis, nosocomial pneumonia, and respiratory diseases like cystic fibrosis. Drugs such as neomycin, tobramycin, gentamicin, amikacin, paromomycin, and streptomycin remain vital in clinical practice, particularly in critical care settings due to their synergy with B-lactam antibiotics against multidrug-resistant organisms. Technological advances, including inhaled forms and semi-synthetic derivatives, have improved drug delivery and safety profiles. Leading companies like Hikma Pharmaceuticals PLC, Pfizer Inc., and Cipla maintain market dominance through extensive product portfolios and geographic expansion.

Market Dynamics

Drivers: Rising incidences of urinary tract infections (UTIs) have increased aminoglycoside prescriptions. Factors such as an aging population, higher prevalence of diabetes, and hospital-acquired infections in developing regions have contributed to this growth. For instance, in February 2024, Cipla Limited received approval from India's CDSCO for Plazomicin, a new IV aminoglycoside indicated for complicated UTIs, including pyelonephritis.

Restraints: The emergence of antimicrobial resistance (AMR) threatens market growth. Resistance in Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa has been rising, complicating treatment outcomes. In July 2023, the U.S. CDC reported an increase in carbapenem-resistant Enterobacteriaceae (CRE) and aminoglycoside-resistant gram-negative bacteria. Similarly, the ECDC noted resistance in K. pneumoniae bloodstream infections exceeding 25% in multiple EU countries.

Opportunities: Development of peptide-linked aminoglycoside conjugates offers potential to combat multidrug-resistant pathogens. In August 2025, a study published in Frontiers in Microbiology highlighted that peptide-neomycin conjugates combined with polymyxin B show synergistic activity against multidrug-resistant gram-negative bacteria, presenting a promising growth avenue.

Challenges: Ototoxicity and nephrotoxicity remain major concerns. Patients with rare mitochondrial mutations are particularly susceptible to irreversible hearing loss, even at therapeutic doses. In January 2021, the UK government reported the narrow therapeutic window of aminoglycosides, highlighting the clinical challenges in urgent care settings and limiting adoption.

Market Trends

The market is witnessing increased adoption of combination therapy. Aminoglycosides are now frequently integrated into multidrug regimens for conditions like NTM lung disease caused by Mycobacterium avium complex (MAC). This approach enhances efficacy, slows resistance development, and extends the therapeutic lifespan of existing antibiotics. In March 2021, Insmed Inc. received approval in Japan for ARIKAYCE (amikacin liposome inhalation suspension), a combination therapy for NTM lung disease.

Segmentation Analysis

By Generation: The third-generation aminoglycosides dominate due to effectiveness against multidrug-resistant infections. Strategic collaborations, such as the June 2022 agreement between Sihuan Pharmaceutical Holdings Group Ltd. and Shanghai SPH New Asia Pharmaceutical Co., Ltd., support the development of third-generation drugs like Plazomicin.

By Application: Respiratory tract infections hold the largest share due to their prevalence and treatment complexity, particularly in cystic fibrosis patients. The CDC reported in May 2024 that approximately 35,000 people in the U.S. are affected by cystic fibrosis, driving aminoglycoside demand.

By Route of Administration: The topical segment dominates due to localized efficacy, minimal systemic absorption, and novel product launches. For example, Appili Therapeutics Inc. developed ATI-1801, a topical paromomycin formulation for cutaneous leishmaniasis, in October 2024.

By Distribution Channel: Retail pharmacies lead due to accessibility, patient trust, and network expansion. In September 2024, Pharmaprix expanded its care clinics in Quebec, improving access to aminoglycosides.

Regional Outlook

North America: Dominates with USD 0.79 billion in 2025, driven by strategic collaborations, R&D investments, and a robust healthcare system.

Europe: Projected to reach USD 0.49 billion in 2025 with a 2.80% growth rate, supported by strong healthcare infrastructure and antimicrobial stewardship programs.

Asia Pacific: Estimated at USD 0.32 billion in 2025, reflecting increasing access to antibiotics and rising infection prevalence.

Latin America & Middle East & Africa: Moderate growth is expected, with USD 0.20 billion in Latin America and smaller contributions from the Middle East & Africa, fueled by increasing healthcare expenditure.

Competitive Landscape

The market exhibits a semi-concentrated structure. Key players like Amneal Pharmaceuticals, Hikma Pharmaceuticals, Cipla, Pfizer Inc., and Insmed Incorporated focus on product innovation, partnerships, and geographic expansion. Notable developments include Nordic Pharma's generic Maxitrol launch in April 2025 and Lupin's Tobramycin inhalation solution FDA approval in June 2018.

Conclusion

The global aminoglycosides market is set to grow from USD 1.92 billion in 2025 to USD 1.96 billion in 2026, reaching USD 2.52 billion by 2034 at a CAGR of 3.17%. Growth is driven by rising urinary tract and respiratory infections, combination therapy adoption, and ongoing R&D to overcome antimicrobial resistance. Challenges such as toxicity risks and resistance issues exist, but advancements in formulation, delivery technologies, and peptide-linked aminoglycosides present significant opportunities. Key players' strategic collaborations and product launches reinforce their market position, ensuring sustained growth over the forecast period.

Segmentation By Generation

  • First Generation
  • Second Generation
  • Third Generation
  • Others

By Application

  • Urinary Tract Infections
  • Respiratory Tract Infection
  • Skin Infections
  • Ophthalmic Infections
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (By Generation, Application, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Key Diseases, By Key Countries/ Region, 2025
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Overview of Antimicrobial Treatment Guidelines
  • 4.5. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
  • 4.6. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Generation
    • 5.1.1. First Generation
    • 5.1.2. Second Generation
    • 5.1.3. Third Generation
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Urinary Tract Infections
    • 5.2.2. Respiratory Tract Infection
    • 5.2.3. Skin Infections
    • 5.2.4. Opthalmic Infections
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Generation
    • 6.1.1. First Generation
    • 6.1.2. Second Generation
    • 6.1.3. Third Generation
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Urinary Tract Infections
    • 6.2.2. Respiratory Tract Infection
    • 6.2.3. Skin Infections
    • 6.2.4. Opthalmic Infections
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Generation
    • 7.1.1. First Generation
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Urinary Tract Infections
    • 7.2.2. Respiratory Tract Infection
    • 7.2.3. Skin Infections
    • 7.2.4. Opthalmic Infections
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Generation
    • 8.1.1. First Generation
    • 8.1.2. Second Generation
    • 8.1.3. Third Generation
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Urinary Tract Infections
    • 8.2.2. Respiratory Tract Infection
    • 8.2.3. Skin Infections
    • 8.2.4. Opthalmic Infections
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Generation
    • 9.1.1. First Generation
    • 9.1.2. Second Generation
    • 9.1.3. Third Generation
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Urinary Tract Infections
    • 9.2.2. Respiratory Tract Infection
    • 9.2.3. Skin Infections
    • 9.2.4. Opthalmic Infections
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Aminoglycosides Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Generation
    • 10.1.1. First Generation
    • 10.1.2. Second Generation
    • 10.1.3. Third Generation
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Urinary Tract Infections
    • 10.2.2. Respiratory Tract Infection
    • 10.2.3. Skin Infections
    • 10.2.4. Opthalmic Infections
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Amneal Pharmaceuticals, Inc.
    • 11.2.2. Hikma Pharmaceuticals PLC
    • 11.2.3. Insmed Incorporated
    • 11.2.4. Pfizer Inc.
    • 11.2.5. Cipla
    • 11.2.6. Nordic Group B.V.
    • 11.2.7. Lupin
    • 11.2.8. Sun Pharmaceutical Industries Ltd.
    • 11.2.9. Dr. Reddy's Laboratories Ltd.

List of Tables

  • Table 1: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 2: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 7: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 8: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Aminoglycosides Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 12: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 13: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 17: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 18: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 22: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 23: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 27: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 28: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Aminoglycosides Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Aminoglycosides Market Value Share (%), by Generation, 2025 & 2034
  • Figure 3: Global Aminoglycosides Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Aminoglycosides Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Aminoglycosides Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Aminoglycosides Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 8: North America Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 9: North America Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 10: North America Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 11: North America Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Aminoglycosides Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Aminoglycosides Market Value Share (%), By Country, 2025
  • Figure 17: Europe Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 18: Europe Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 19: Europe Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 20: Europe Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 21: Europe Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 28: Asia Pacific Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 29: Asia Pacific Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 30: Asia Pacific Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 31: Asia Pacific Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 38: Latin America Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 39: Latin America Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 40: Latin America Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 41: Latin America Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Aminoglycosides Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 48: Middle East & Africa Aminoglycosides Market Value Share (%), by Generation, 2025
  • Figure 49: Middle East & Africa Aminoglycosides Market Value (USD billion), by Application, 2025 & 2034
  • Figure 50: Middle East & Africa Aminoglycosides Market Value Share (%), by Application, 2025
  • Figure 51: Middle East & Africa Aminoglycosides Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Aminoglycosides Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Aminoglycosides Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Aminoglycosides Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Aminoglycosides Market Share (%), By Company, 2025